Zydus Cadila has received the final approval from the USFDA to market Piroxicam Capsules USP (US RLD - Feldene Capsules) in strengths of 10 mg and 20 mg. It is a non-steroidal anti-inflammatory drug indicated for symptomatic treatment of osteoarthritis and rheumatoid arthritis. It will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.
In line with this, the group now has 209 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.354.1 as compared to the previous close of Rs. 359.5. The total number of shares traded during the day was 95022 in over 2140 trades.
The stock hit an intraday high of Rs. 366.1 and intraday low of 348.7. The net turnover during the day was Rs. 33950395.